Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Melanoma models for the next generation of therapies.
Patton EE, Mueller KL, Adams DJ, Anandasabapathy N, Aplin AE, Bertolotto C, Bosenberg M, Ceol CJ, Burd CE, Chi P, Herlyn M, Holmen SL, Karreth FA, Kaufman CK, Khan S, Kobold S, Leucci E, Levy C, Lombard DB, Lund AW, Marie KL, Marine JC, Marais R, McMahon M, Robles-Espinoza CD, Ronai ZA, Samuels Y, Soengas MS, Villanueva J, Weeraratna AT, White RM, Yeh I, Zhu J, Zon LI, Hurlbert MS, Merlino G. Patton EE, et al. Among authors: burd ce. Cancer Cell. 2021 May 10;39(5):610-631. doi: 10.1016/j.ccell.2021.01.011. Epub 2021 Feb 4. Cancer Cell. 2021. PMID: 33545064 Free PMC article. Review.
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.
Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, Mills GB, Sullivan RJ, Benchun M, Frederick DT, Boland G, Flaherty KT, Weeraratna AT, Herlyn M, Amaravadi R, Schuchter LM, Burd CE, Aplin AE, Xu X, Villanueva J. Echevarría-Vargas IM, et al. Among authors: burd ce. EMBO Mol Med. 2018 May;10(5):e8446. doi: 10.15252/emmm.201708446. EMBO Mol Med. 2018. PMID: 29650805 Free PMC article.
Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity.
Phadke MS, Chen Z, Li J, Mohamed E, Davies MA, Smalley I, Duckett DR, Palve V, Czerniecki BJ, Forsyth PA, Noyes D, Adeegbe DO, Eroglu Z, Nguyen KT, Tsai KY, Rix U, Burd CE, Chen YA, Rodriguez PC, Smalley KSM. Phadke MS, et al. Among authors: burd ce. Cancer Immunol Res. 2021 May;9(5):554-567. doi: 10.1158/2326-6066.CIR-20-0905. Epub 2021 Mar 2. Cancer Immunol Res. 2021. PMID: 33653716 Free PMC article.
UVB mutagenesis differs in Nras- and Braf-mutant mouse models of melanoma.
Bowman RL, Hennessey RC, Weiss TJ, Tallman DA, Crawford ER, Murphy BM, Webb A, Zhang S, La Perle KM, Burd CJ, Levine RL, Shain AH, Burd CE. Bowman RL, et al. Among authors: burd ce, burd cj. Life Sci Alliance. 2021 Jul 1;4(9):e202101135. doi: 10.26508/lsa.202101135. Print 2021 Sep. Life Sci Alliance. 2021. PMID: 34210801 Free PMC article.
Topical therapy for regression and melanoma prevention of congenital giant nevi.
Choi YS, Erlich TH, von Franque M, Rachmin I, Flesher JL, Schiferle EB, Zhang Y, Pereira da Silva M, Jiang A, Dobry AS, Su M, Germana S, Lacher S, Freund O, Feder E, Cortez JL, Ryu S, Babila Propp T, Samuels YL, Zakka LR, Azin M, Burd CE, Sharpless NE, Liu XS, Meyer C, Austen WG Jr, Bojovic B, Cetrulo CL Jr, Mihm MC, Hoon DS, Demehri S, Hawryluk EB, Fisher DE. Choi YS, et al. Among authors: burd ce. Cell. 2022 Jun 9;185(12):2071-2085.e12. doi: 10.1016/j.cell.2022.04.025. Epub 2022 May 12. Cell. 2022. PMID: 35561684 Free PMC article.
Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma.
Jeck WR, Parker J, Carson CC, Shields JM, Sambade MJ, Peters EC, Burd CE, Thomas NE, Chiang DY, Liu W, Eberhard DA, Ollila D, Grilley-Olson J, Moschos S, Neil Hayes D, Sharpless NE. Jeck WR, et al. Among authors: burd ce. Pigment Cell Melanoma Res. 2014 Jul;27(4):653-63. doi: 10.1111/pcmr.12238. Epub 2014 Apr 7. Pigment Cell Melanoma Res. 2014. PMID: 24628946 Free PMC article. Clinical Trial.
Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.
Burd CE, Liu W, Huynh MV, Waqas MA, Gillahan JE, Clark KS, Fu K, Martin BL, Jeck WR, Souroullas GP, Darr DB, Zedek DC, Miley MJ, Baguley BC, Campbell SL, Sharpless NE. Burd CE, et al. Cancer Discov. 2014 Dec;4(12):1418-29. doi: 10.1158/2159-8290.CD-14-0729. Epub 2014 Sep 24. Cancer Discov. 2014. PMID: 25252692 Free PMC article.
53 results